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1. Introduction 
The worsening of glucose metabolism as well as increasing risk for cardiovascular disease 
while aging is documented (Wild S. et al., 2004; Okereke OI. et al., 2008). According to gold 
standard research in diabetes - the United Kingdom Prospective Diabetes Study (UKPDS) 
(Matthews D.R 1999; Turner R.C. et al., 1998) - about 40% of patients with type 2 diabetes 
mellitus (T2DM) suffer from late diabetic complications, including  atherosclerosis, 
hypertension and dyslipidemia and microangiopathies (nephropathy, retinopathy). From 
epidemiological point of view, 40% of dysglycemic patients are 65 years old or over (Barnett 
T. 1998; Harris M. 19962). 
An impaired fasting glycemia (IFG) and an impaired glucose tolerance (IGT) are categories of 
increased risk for type 2 diabetes mellitus (prediabetes) (ADA 2012). There is no separate 
algorithm for dysglycaemia in elders, however glucose concentrations in plasma increases with 
aging (from 30 years old, fasting glycemia about 1-2 mg/dl for the every decade and 
postprandial glycaemia about 2-4 mg/dl for the every decade), and is caused by insulin-
resistance (Winger JM & Hornick T. 1996). Paralleled to glucose concentration glycated 
hemoglobin - HbA1c rise with age – round 0,11 to 0,15 % of HbA1c per decade (Nuttal F.Q.  1999). 
Aging is a universal process that can be determined by genetic, the environment or diseases. 
Biological theories are the most promising in relation to finding answers about aging.  
1.1. Aging theories   
There are many aging theories. From the very easy one, like programmed death theories, to 
the more complicated as concerning mistake accumulation theories (Table 1).  
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THEORIES  
OF PROGRAMED DEATH 
THEORIES 
OF MISTAKE ACCUMULATION 
 
programmed cellular aging theory 
clock theory 
autoimmune theory 
random mistake theory 
free radical theory 
cross-links theory 
calories restriction theory 
glycation theory 
Table 1. Theories of aging (examples) 
The gerontological theories try to explain aging from the biological point of view, and 
explain that not only still dividing cells but also cells that are unable to divide, both can be 
targeted by aging (Kirkwood TBL. & Austad SN. 2000). 
1.1.1. Free radical theory 
The free radicals theory postulates that the aging process is the initiation of free radical 
reactions (Harman D. 2003) and in hyperglycemic patients may rise due to increased free 
radicals production. The theory suggests that most of free radicals are initiated and 
produced by mitochondria and a life span is determined by the rate of free radical damage 
to the mitochondria (Harman D. 1983). 
1.1.2. Glycation theory 
The theory is based on non-enzymatic reaction - glycation. The theory suggests that glucose 
acts a mediator of aging. The cross-links between glucose and proteins lead to stable intra- 
and inter-molecular changes which can influence cells, tissues and organs (Soškić V. et al., 
2008). Thus the glycation may have tremendous cumulative effect during a person's life 
leading to shorter life span in diabetics. 
1.1.3. Caloric restriction 
The theory proposes that life span can be prolonged by lover calorie intake but the 
compounds are the full qualitative (Vitetta L. & Anton B. 2007). Decreases in calorie intake 
reduce free radicals production – lower oxidative stress and decreased inflammatory 
processes (Ungvari Z. et al., 2008).  
Patients with hyperglycemia may present more than one reason of increased aging process. 
1.2. Late complications of hyperglycemia 
As hyperglycemia starts (prediabetes, diabetes mellitus) late metabolic complications, 
caused by glucose toxicity (Robertson RP. & Harmon JS. 2006), oxidative stress (Cumaoğlu 
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A. et al., 2010), dyslipidemia (Gordon L. et al., 2010), increased polyol pathway (Obrosova 
I.G. 2005) and glycation of protein (Xie X. et a., 2010), increase. 
1.3. Protein glycation 
Protein glycation and oxidative stress in a context of aging is widely discussed (Robertson 
RP. 2004; Muller F.L. et al., 2007; Soškić V., et al. 2008). Protein glycation depends on duration 
of hyperglycemia and increase in aging and co-morbidities (Peppa M. & Vlassara H. 2005).  
Non-enzymatic glycation of proteins leads trough Amadori products such as glycated 
albumine (fructosamine), glycated hemoglobine (HbA1c) to Advanced Glycation End 
Products (AGEs) eg. Nε-carboxymethyllysine (CML) (figure 1), bio-active molecules which 
accumulate with age. AGEs are produced in human as a part of normal metabolism, but are 
elevated in diabetic patients, and depends on hyperglycemia duration and level (higher and 
longer hyperglycemia leads to higher AGEs concentration). 
 
Figure 1. Pathways for the Advanced End Products Formation i.e. Nε-carboxymethyllysine. 
 
lipid peroxidation sorbitol GLUCOSE + N-terminal 
protein 
Schiff Base
fructose 
phosphoranes 
fermentation
ketones 
katabolism 
Amadori product 
i.e. FRUCTOSAMINE, 
GLYCATED HEMOGLOBINE (HbA1c) 
glioksal methylglioksal
oxidative pathway
α- oxoaldehyde
Nε-CARBOXYMETHYLLYSINE (CML)
 
Glucose Tolerance 84 
1.3.1. Fructosamine 
Fructosamine is an Amadori product that is formed as a result of lysine side chain of protein 
modification by glucose and its serum level is reported to increase in diabetes. The product 
serves as short term marker (2-3 weeks) of glycemic control (Armbruster DA.1987; True 
MW. 2009). Fructosamine can undergo oxidative cleavage leading to the formation of 
Avanced Glycation End products (AGEs), which are implicated in long-term complications 
of diabetes mellitus.  
1.3.2. Glycated hemoglobin, HbA1c 
Glycated hemoglobin, HbA1c, is an Amadori product that is now recognized as a marker of 
glycemic control. Glycated hemoglobine, HbA1c measures blood glucose control over a 
period of eight to twelve weeks (Rohlfing CL. et al., 2002). The results from different trials 
(The ACCORD trial (ACCORD Group 2008), the Veterans Affairs Diabetes Trial (VADT 
Investigators 2009), the Action in Diabetes and Vascular Disease—PreterAx and DiamicroN 
Modified Release Controlled Evaluation (ADVANCE) trial (ADVANCE Collaborative 
Group 2009)), have created a debate about the optimal choice of glycated hemoglobine 
target. The International Diabetes Federation recommends a level of less than 6.5% (IDF 
2006) whereas the American Diabetes Association recommends an HbA1c level of less than 
7.0% as the standard of glycemic treatment goal (ADA 2010). the American Diabetes 
Association recommends a HbA1c level of less than 8.0% as the glycemic treatment goal for 
the elderly diabetic persons. Nowadays the HbA1c is also recommended for diagnosis of 
diabetes (ADA 2010). 
1.3.3. Advanced glycation end products - Nε-carboxymethyllysine, CML 
Nε-carboxymethyllysine, {(2S)-2-amino-6-(carboxymethylamino)hexanoic acid}, (CML), 
(figure 2) one of dominant Advanced Glycation End products (AGEs), is formed in vivo by 
oxidative cleavage of the Amadori product threulosyl-lysine (combined non-enzymatic 
glycation and  glycoxidation) and of metal-catalyzed oxidation of LDL or peroxidation of 
polyunsaturated fatty acids in the presence of fructose-lysine (Fu M.X. et al., 1996) (As in 
figure 1). Thus CML may serve as bio-marker of oxidative stress and protein damage in 
aging, diabetes mellitus and atherosclerosis (Southern L. et al., 2007; Semba R. D. et al., 
2009). Excessive formation of CML has been proposed to be an important mechanism for 
accelerated atherogenesis in patients with hyperglycemia.  
There are many evidences indicating that protein glycation and oxidative stress may 
accompany and explain metabolic late diabetic complications. Investigation of glycated 
proteins (fructosamine, HbA1c) and AGEs (i.e. CML), in early stages of glucose metabolism 
problems, may explain metabolic complications in hyperglycemic elderly persons.  
The aim of the study was to analyze fructosamine in plasma, HbA1c in blood and CML 
serum concentrations among elderly patients with increased risk for type 2 diabetes mellitus 
(prediabetes) and normal glucose tolerance. 
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Figure 2. Chemical structure of Nε-carboxymethyllysine, (2S)-2-amino-6-
(carboxymethylamino)hexanoic acid, (CML) – one of the Advanced Glycation End product. 
2. Material and methods 
The study was performed in the Department of Clinical Biochemistry and Laboratory 
Medicine, Chair of Chemistry and Clinical Biochemistry of Poznan University of Medical 
Sciences under the permission from local ethics group in accordance with the Declaration of 
Helsinki of 1975 for Human Research and the study protocol was approved by the Bioethics 
Committee of Poznan University of Medical Sciences in Poznan, Poland. 
Subjects and Settings: This study population consisted of 313 elderly Caucasians (65 and 
older) from Poznan metropolitan area, and after following exclusion criteria (below), 58 of 
them with no acute diseases or severe chronic disorder were enrolled to the study. They were 
performed complete physical examination including the measurement of waist circumference 
(WC) in centimeters, percentage of body fat (FAT) by bioimpedance using BodyStat 
equipment and the calculation of body mass index (BMI=kg/m2). Arterial blood pressure: 
systolic (SBP) and diastolic (DBP) were measured twice by sphyngomanometer MEDEL 
PALM PRO No: 91431 (Novamedica Ltd, Birmingham, United Kingdom) in sitting position, 
after at least 5 minutes rest. The arterial blood pressure was expressed than as mean value.  
The exclusion criteria were the presence of following conditions: a coronary artery disease, a 
history of diabetes, the neoplastic diseases, the inflammatory diseases, a previous therapy, 
use of anti- and oxidant drugs, alcohol use, smoking and electrocardiography findings 
specific for myocardial ischaemia/infarct.  
Additional biochemical exclusion criteria were microalbuminuria and macroalbuminuria as 
albumin/creatinin ratio > 30 mg of albumin/1 g of creatinin in fresh morning urine sample 
and decreased estimated Glomerular Filtration Rate (eGFR) less than 60 ml/min/m2 based on 
Modified Diet in Renal Diseases (MDRD) formula: 
eGFR (ml/min/1.75m2) = 
= {186 x [creatynin]-1,154 x [age] -0,203 x 0,742 [for women] x 1,210 [for Afroamerican]} 
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Blood sampling and biochemical analysis: The studied subjects were collected ulnar 
venous blood twice: at 0 minute (fasting) and at 120 minute of the 75,0-g OGTT. Fasting 
plasma samples without hemolysis were used for glucose and lipid determinations. Fasting 
serum samples designated for fructosamine and Nε-carboxymethyllysine measurements 
were frozen and stored at –25o C until assayed, separately. Blood collected at 120 minute of 
OGTT was used for plasma glucose determination. 
Glucose and lipids assay. Oral glucose tolerance test (OGTT) was performed according to 
WHO recommendations (WHO 1999) between 7.00-9.00 am. Glucose concentration was 
determined at 0 min (fasting) and 120 min (postprandial) following a standard dose of 75 g 
glucose load. Glucose and lipid parameters including total cholesterol (T-C), high density 
lipoproteins cholesterol (HDL-C), triacyloglycerydes (TG) concentrations were evaluated by 
enzymatic methods using bioMerieux reagent kit (Marcy-l’Etoile, France) and the UV-160A 
Shimadzu spectrophotometer (Shimadzu Co., Kyoto, Japan). Low density lipoproteins 
cholesterol (LDL-C) was calculated using the Friedewald formula: 
LDL-C [mmol/l]={[(T-C)-(HDL-C)]-(TG/2,2)}  
The reference sera: RANDOX Assayed Human Multi Sera Level 1 (as normal) and 
RANDOX Assayed Human Multi Sera Level 2 (as pathological) (Randox, Crumlin, United 
Kingdom) were used for monitoring the accuracy of the determinations.  
Results of OGTT allowed to classify subjects for normal glucose tolerance (NGT) (n=30, 
mean age 69,5 years) and prediabetic (PRE) (n=20, mean age 70,0 years) categories, while 
newly diagnosed type 2 diabetes mellitus (T2DM) patients were excluded from the study. 
The interpretation of oral glucose tolerance test is presented in Table 2 (ADA 2012). 
 
Categories of glycemia  
during OGTT 
 Plasma glucose concentration 
 Fasting (at 0 min.) at 120 min. 
Normal glucose tolerance (NGT ) < 5,6 mmol/l 
< 100 mg/dl  
< 7,8 mmol/l 
< 140 mg/dl  
High risk  
of diabetes 
(Prediabetes, 
PRE) 
Impaired Fasting Glycemia (IFG) 5,6 – 6,9 mmol/l 
100 – 125 mg/dl  
< 7,8 mmol/l 
< 140 mg/dl  
Impaired Glucose Tolerance (IGT) < 7,0 mmol/l 
< 126 mg/dl 
7,8 – 11,0 mmol/l 
140 –199 mg/dl  
Diabetes mellitus (DM) < 7,0 mmol/l 
< 126 mg/dl  
≥ 11,1 mmol/l 
≥ 200 mg/dl  
Table 2. The interpretation of oral glucose tolerance test (OGTT)  
Fructosamine assay. Glycated albumine (fructosamine) was determined using calorymetric 
metod based on the ability of ketoamines to reduce nitrotetrazolium-blue (NBT) to formazan 
in an alkaline solution. The rate of formation of formazan is directly proportional to the 
concentration of fructosamine. The measurement was done by Cobas 400 (Roche 
Diagnostics, Mannheim, Germany).  
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The sensitivity of this assay was 0,14 μmol/l with intra-assay coefficient of variation (CV) 
and inter-assay CV precision at 2,8% and 0,65% respectively.  
HbA1c assay. Glycated hemoglobin, (HbA1c) was determined using ion exchange high 
performance liquid chromatography (HPLC), D-10 (BioRad, Heidelberg, Germany). Using a 
specific standardized measurement set established through the National Glycohemoglobin 
Standardization Program (NGSP). The sensitivity of this assay was 0,05% with intra-assay 
coefficient of variation (CV) and inter-assay coefficient of variation (CV) precision at 2,35% 
and 2,66% respectively.  
Nε-carboxymethyllysine {(2S)-2-amino-6-(carboxymethylamino)hexanoic acid} assay. 
Fasting plasma samples were drown and the concentration of Nε-carboxymethyllysine 
(CML) was measured with a novel competition-based ELISA assay using a CML-specific 
monoclonal antibody ELISA kit (MicroCoat, Bernried am Starnberger See, Germany). 
Absorbance was read using a microtitre ELISA plate reader (SunriseTM, Tecan Group Ltd, 
Männedorf, Switzerland) at 405 nm. CML concentrations were obtained from standard 
curve (linear/linear plot method) and expressed in ng/ml. All samples were run in triplicate. 
The sensitivity of this competitive ELISA assay was 5 ng/ml with intra-assay coefficient of 
variation (CV) and inter-assay CV precision at 5% and 6,8% respectively.  
Statistical Analysis Statistica (version 6.0) for Windows was used for statistical analysis. 
The normality of value distribution was checked by Shapiro-Wilk test. Then, the results with 
a Gaussian distribution were analyzed with Student’s t test, and those with a non-Gaussian 
distribution with a nonparametric Mann-Whitney U test to assess the differences between 
studied groups. The Spearman rank correlation test was used to evaluate the strength of 
association between two variables. A p<0.05 was considered statistically significant.  
Sensitivity, specificity and the highest diagnostic value for the fructosamine, HbA1c, CML 
level we obtain based on ROC curves analysis using MedCalc® v. 9.3.7.0 for Windows. ROC 
curves analyses were used to determine the optimal values of fructosamine, glycated 
hemoglobine (HbA1c) and Nε-carboxymethyllysine (CML) distinguishing between normal 
and disturbed glucose tolerance groups. 
All results are shown as mean ± standard deviation (SD) and median (in brackets). 
3. Results 
In our study group, after ruling out those with any disease, patients were divided into: 
normoglycemic (n=30), prediabetes (n=20) and as newly diagnosed diabetes mellitus type 2 
(n=8) (based on oral glucose tolerance test, see methods). The newly diagnosed diabetes type 
2 were excluded than. All investigated patients were normoalbuminuria staged and eGFR > 
60ml/min/m2.  
3.1. Comparison of normoglycemic (NGT) and prediabetic (PRE) subjects 
Table 3 shows the baseline characteristics and clinical parameters of the elderly normal 
glucose tolerance subjects (NGT) and elderly prediabetes patients (PRE) according to Oral 
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Glucose Tolerance Test (OGTT). The groups by definition were different as far as glucose 
concentration was concerned (both fasting and postprandial) (p=0,0000002 and p=0,000009 
respectively). 
The investigated groups did not differ in clinical parameters such as arterial blood pressure 
and anthropometric factors (BMI, body fat, waist circumference) as well as plasma lipids.  
 
 
 
NGT (n=30) 
Mean  ±  SD 
(Median) 
PRE (n=20) 
Mean  ±  SD 
(Median) 
p 
Age [years] 70,6 ± 8,4 (69,5) 70,2 ± 5,27 (70,0) NS 
BMI [kg/m2] 27,9 ± 4,4 (26,6) 30,8 ± 5,5 (30,0) NS 
Waist [cm] 91,0 ± 7,1 (92,0) 95,5 ± 12,8 (93,0) NS 
FAT [%] 36,1 ± 17,6 (45,0) 38,3 ± 11,8 (41,5) NS 
SBP [mmHg] 136,4 ± 13,8 (135,0) 142,9 ± 11,0 (140,0) NS 
DBP[mmHg] 83,2 ± 8,8 (85,0) 78,2 ± 8,5 (80,0) NS 
G0' [mmol/l] 5,0 ± 0,5 (5,0) 5,8 ± 0,5 (5,8) 
by def.: 
p=0,000002 
G120' [mmol/l] 5,2 ± 1,2 (5,2) 7,2 ± 1,3 (7,2) 
by def.: 
p=0,000009 
Fructosamine [μmol/l] 253,5 ± 26,6 (255,0) 258,3 ± 27,8 (253,5) NS 
HbA1c [%] 5,85 ± 0,40 (5,85) 6,22 ± 0,47 (6,30) p<0,005 
CML [ng/ml] 2248,7 ± 375,9 (2292,4) 
2079,9 ± 418,9 
(1987,0) 
NS 
TC [mmol/l] 4,98 ± 0,72  (5,01) 5,05 ± 0,89 (5,00) NS 
TG [mmol/l] 1,16 ± 0,50 (0,94) 1,54 ± 0,98 (1,24) NS 
HDL-C [mmol/l] 1,65 ± 0,36 (1,66) 1,46 ± 0,30 (1,44) NS 
LDL-C[mmol/l] 2,82 ± 0,71 (2,88) 2,90 ± 0,72 (2,82) NS 
p – the probability of obtaining a test statistic, SD – standard deviation, NS – not significant, by def. - by definition, 
NGT – normoglycemic group, PRE – prediabetic group, BMI – Body  Mass Index, FAT – body fat, SBP – systolic blood 
pressure, DBP – diastolic blood pressure, G0' – fasting glucose, G120' - postprandial glucose, measured at 120 min after 
75 grams glucose load, HbA1c – glycated hemoglobin, CML – Nε-carboxymethyllysine, TC – total cholesterol, TG – 
triglycerides, HDL-C – high density lipoproteins cholesterol, LDL-C – low density lipoproteins cholesterol, 
Table 3. Baseline characteristics and clinical parameters of the normal glucose tolerance subjects (NGT) 
and prediabetes patients (PRE) according to Oral Glucose Tolerance Test (OGTT). 
The glycated albumin - fructosamine did not differ between investigated groups (Figure 3) 
whereas glycated hemoglobin HbA1c were higher in the prediabetes individuals (p<0,005) 
(Figure 4).   
The CML did not differentiate normoglycemic and prediabetes elderly persons (Figure 5). 
Different correlations between glycated proteins (fructosamine and HbA1c) and metabolic 
parameters were found in analyzed subgroups (table 4 and 5 respectively) at p<0,01. There 
were no correlations in any investigated groups for the CML (table 6). 
ROC curve analysis yielded a fructosamine concentration of the highest diagnostic value in 
distinguishing PRE and NGT (<=237 μmol/l, 29.0% sensitivity and 88,2% specificity, 
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AUC=0,511) based on OGTT (Figure 6). ROC curve analysis yielded a HbA1c percentage of 
the highest diagnostic value in distinguishing PRE and NGT (>6,1 %, 54,8% sensitivity and 
88,2% specificity, AUC=0,679) based on OGTT  (Figure 7). ROC curve analysis yielded a CML 
concentration of the highest diagnostic value in distinguishing PRE and NGT (<=2403,2 
ng/ml, 76.7% sensitivity and 41,2% specificity, AUC=0,548) based on OGTT (Figure 8). 
 
Figure 3. Comparison of fructosamine between normoglycemic subjects (NGT, 0) and prediabetic 
patients (PRE, 1). 
 
Figure 4. Comparison of glycated hemoglobin (HbA1c) between normoglycemic subjects (NGT, 0) and 
prediabetic patients (PRE, 1).  
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Figure 5. Comparison of CML between normoglycemic subjects (NGT, 0) and prediabetic patients 
(PRE, 1). 
 
p<0,01 All persons (n=50) NGT (n=30) PRE (n=20) 
Fructosamine & BMI NS NS NS 
Fructosamne & waist NS NS NS 
Fructosamine & FAT R=0,39 NS NS 
Fructosamine & SBP NS NS NS 
Fructosamine & DBP NS NS NS 
Fructosamine & G0' NS NS NS 
Fructosamine & G120' NS R=0,48 NS 
Fructosamine & TC NS NS NS 
Fructosamine & TG NS NS NS 
Fructosamine & HDL-C NS NS NS 
Fructosamine & LDL-C NS NS NS 
p – the probability of obtaining a test statistic, NS – not significant, NGT – normoglycemic group, PRE – prediabetic 
group, BMI – Body  Mass Index, FAT – body fat, SBP – systolic blood pressure, DBP – diastolic blood pressure, G0' – 
fasting glucose, G120' (postprandial glucose) measured at 120 min after 75 grams glucose load, TC – total cholesterol, 
TG – triglycerides, HDL-C – high density lipoproteins cholesterol, LDL-C – low density lipoproteins cholesterol, 
 
Table 4. Correlation for fructosamine in all investigated persons, NGT and PRE groups. 
p - not significant
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p<0,01 All (n=50) NGT (n=30) PRE (n=20) 
HbA1c  BMI NS NS R=-0,78 
HbA1c  and waist R=0,39 NS NS 
HbA1c  and FAT NS NS NS 
HbA1c  and SBP NS NS NS 
HbA1c  and DBP NS NS NS 
HbA1c and G0' R=0,45 NS NS 
HbA1c and G120' R=0,58 0,51 NS 
HbA1c and TC NS NS NS 
HbA1c and TG NS NS NS 
HbA1c and HDL-C R=-0,47 NS NS 
HbA1c and LDL-C NS NS NS 
p – the probability of obtaining a test statistic, NS – not significant, NGT – normoglycemic group, PRE – prediabetic 
group, BMI – Body  Mass Index, FAT – body fat, SBP – systolic blood pressure, DBP – diastolic blood pressure, G0' – 
fasting glucose, G120' (postprandial glucose) measured at 120 min after 75 grams glucose load, HbA1c – glycated 
hemoglobin, TC – total cholesterol, TG – triglycerides, HDL-C – high density lipoproteins cholesterol, LDL-C – low 
density lipoproteins cholesterol, 
 
Table 5. Correlation for HbA1c in all investigated persons, NGT and PRE groups. 
 
 
p<0,01 All (n=50) NGT (n=30) PRE (n=20) 
CML and BMI NS NS NS 
CML and waist NS NS NS 
CML and FAT NS NS NS 
CML and SBP NS NS NS 
CML and DBP NS NS NS 
CML and G0' NS NS NS 
CML and G120' NS NS NS 
CML and TC NS NS NS 
CML and TG NS NS NS 
CML and HDL-C NS NS NS 
CML and LDL-C NS NS NS 
p – the probability of obtaining a test statistic, NS – not significant, NGT – normoglycemic group, PRE – prediabetic 
group, BMI – Body  Mass Index, FAT – body fat, SBP – systolic blood pressure, DBP – diastolic blood pressure, G0' – 
fasting glucose, G120' (postprandial glucose) measured at 120 min after 75 grams glucose load, CML – Nε-
carboxymethyllysine, TC – total cholesterol, TG – triglycerides, HDL-C – high density lipoproteins cholesterol, LDL-C 
– low density lipoproteins cholesterol, 
 
Table 6. Correlation for CML in all investigated persons, NGT and PRE groups. 
 
Glucose Tolerance 92 
 
 
 
Figure 6. Receiver operating characteristic (ROC) curve for fructosamine diagnostic value (sensitivity 
and specificity) in distinguishing between normal glucose tolerance subjects (NGT) and prediabetic 
patients (PRE) classified according to OGGT results. 
 
 
 
Figure 7. Receiver operating characteristic (ROC) curve for HbA1c diagnostic value (sensitivity and 
specificity) in distinguishing between normal glucose tolerance subjects (NGT) and prediabetic patients 
(PRE) classified according to OGGT results. 
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Figure 8. Receiver operating characteristic (ROC) curve for CML diagnostic value (sensitivity and 
specificity) in distinguishing between normal glucose tolerance subjects (NGT) and prediabetic patients 
(PRE) classified according to OGGT results. 
3.2. Comparison of two prediabetic (PRE) subgroups: Impaired Fasting Glucose 
(IFG) and Impaired Glucose Tolerance (IGT) subjects 
Table 7 shows the baseline characteristics and clinical parameters of the Impaired Fasting 
Glucose subjects (IFG) and Impaired Glucose Tolerance subjects (IGT) subgroups of 
prediabetic elderly patients according to Oral Glucose Tolerance Test (OGTT).  The 
subgroups by definition were different as far as glucose concentration was concerned (both 
fasting and postprandial) (p=0,01 and p=0,001 respectively). Otherwise the prediabetic 
subgroups did not differ in clinical parameters as well as biochemical factors. However the 
glycated hemoglobin (HbA1c) had tendency to be higher in the Impaired Glucose Tolerance 
individuals and the glycated albumin - fructosamine and Advanced Glycation End Product 
- Nε-carboxymethyllysine had tendency to be higher in Impaired Fasting Glucose subjects.  
4. Disscusion 
One of the fundamental elements for establishing prevention, treatment and prognosis of 
diabetes mellitus is an assessment of the clinical stage of glucose metabolism problems.  
Dysglycemia population is recognized with increased cardiovascular morbidity and 
mortality [Khaw KT. Et al., 2004; Sung J. et al. 2009). The cumulative effect of many metabolic 
risk factors (clinical and biochemical) in one individual which influenced cardiovascular risk 
are widely discussed (Selvin E. et al., 2005; Gerstein HC. et al., 2005). In our study we 
investigated elderly otherwise healthy persons. We found that in those with the increased 
risk for the type 2 diabetes mellitus (prediabetes) there were more (but not significant) 
indicators for the metabolic syndrome (obesity, abdominal obesity, systolic  hypertension).     
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IFG (n=8) 
Mean  ±  SD 
(Median) 
IGT (n=12) 
Mean  ±  SD 
(Median) 
p 
Age [years] 69,8 ± 3,8 (69,0) 70,2 ± 6,56 (70,0) NS 
BMI [kg/m2] 30,4 ± 6,8 (29,0) 31,7 ± 4,6 (30,5) NS 
Waist [cm] 96,0 ± 13,8 (91,5) 96,5 ± 12,9 (94,0) NS 
FAT [%] 35,3 ± 12,6 (38,8) 39,8 ± 12,2 (44,4) NS 
SBP [mmHg] 141,7 ± 12,1 (142,5) 142,0 ± 10,8 (140,0) NS 
DBP[mmHg] 76,7 ± 8,8 (72,5) 79,0 ± 9,1 (80,0) NS 
G0' [mmol/l] 6,3 ± 0,5 (6,4) 6,3 ± 0,5 (6,8) 
by def.: 
p=0,01 
G120' [mmol/l] 6,6 ± 1,0 (7,0) 8,8 ± 1,0 (9,1) 
by def.: 
p=0,001 
Fructosamine [μmol/l] 261,8 ± 27,5 (267,0) 257,0 ± 30,5 (253,5) NS 
HbA1c [%] 6,04 ± 0,60 (5,90) 6,35 ± 0,37 (6,40) NS 
CML [ng/ml] 2123,9 ± 375,5 (2122,7) 2053,4 ± 443,1 (1987,0) NS 
TC [mmol/l] 4,85 ± 0,86  (4,74) 5,41 ± 0,89 (5,25) NS 
TG [mmol/l] 1,22 ± 0,47 (1,18) 1,73 ± 1,2 (1,14) NS 
HDL-C [mmol/l] 1,53 ± 0,42 (1,50) 1,51 ± 0,32 (1,50) NS 
LDL-C[mmol/l] 2,76 ± 0,83 (2,92) 3,09 ± 0,61 (2,87) NS 
p – the probability of obtaining a test statistic, SD – standard deviation, NS – not significant, by def. - by definition, 
NGT – normoglycemic group, PRE – prediabetic group, BMI – Body  Mass Index, FAT – body fat, SBP – systolic blood 
pressure, DBP – diastolic blood pressure, G0' – fasting glucose, G120' - postprandial glucose, measured at 120 min after 
75 grams glucose load, HbA1c – glycated hemoglobin, CML – Nε-carboxymethyllysine, TC – total cholesterol, TG – 
triglycerides, HDL-C – high density lipoproteins cholesterol, LDL-C – low density lipoproteins cholesterol, 
Table 7. Baseline characteristics and clinical parameters of the prediabetes (PRE) subgroups the 
Impaired Fasting Glucose subjects (IFG) and the Impaired Glucose Tolerance subjects (IGT) according 
to Oral Glucose Tolerance Test (OGTT). 
We had hoped while performing those analysis to find a set of laboratory measures that 
would provide a better indicator of a prediabetic elderly persons for glycemic control than 
any one measure alone. 
The amount of glycated proteins (fructosamine and HbA1c) depend on time-averaged 
glucose concentration. Thus fructosamine and HbA1c reflect the extent of exposure to 
glucose in the 2-4 and 8-12 weeks before testing, respectively. Since 2010, American Diabetes 
Association has added a new recommendation for diagnosis of diabetes mellitus, concerning 
not only based on hyperglycemia (random, fasting or due to OGTT) but also glycated 
hemoglobin HbA1c (ADA 2010).  
The primary aim of the study was to evaluate the blood levels of glycated proteins and CML 
in two clinical situations, normal glucose tolerance and prediabetic state in elderly patients. 
Our study showed that the glycated hemoglobin corresponded better in distinguishing the 
NGT from PRE in the investigated elderly persons than fructosamine or advanced glycation 
end product – Nε-carboxymeethyllysine.   
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Hyperglycemia and oxidative stress accelerate not only glycation of proteins such as 
hemoglobin but also leads to Advanced Glycated End Products (AGEs) such as Nε-
carboxymethyllysine (CML). During natural aging AGEs accumulate and the 
concentration of formers depends on time and progressive reduction in the capacity to 
neutralise oxidative stress and may leads to many complications such as atherosclerosis 
and dementia (Hipkiss AR., 2006; Semba RD. et al., 2010). In 2003 Hamelin M. and 
collegues established that CML are increased in the rat serum with aging (Hamelin M. et 
al., 2003). So is CML independent risk factor for aging or rather diseases? Our study 
focused on CML in elderly group at the earliest stages of hyperglycemia. Our investigated 
groups had no known clinical and laboratory complications, in all subgroups CML 
concentration is very high in comparison with others investigators. Ahmed K.A. et al. 
excluded the effect of age on CML concentration in type 2 diabetic patients with ischemic 
heart disease (Ahmed K.A. et al., 2007). They argued that increased CML concentration 
was an independent from other risk factors for the coronary artery disease (CAD) in type 
2 diabetes mellitus and ha significant predictive power to CAD especially in type 2 
diabetes mellitus (Ahmed K.A. et al., 2008). In our investigated groups CML concentration 
were higher in comparison with CML concentration in Ahmed work. Our investigated 
study patients were either with normal glucose metabolism or prediabetes stage, both 
elderly patients with no clinical complications such as CAD or kidney failure. CML 
concentration depends on proteins glycation but also is directly proportional to creatinine 
concentration and inversely proportional to glomerular filtration rate. Hirata K. work 
showed that CML is increased in type 2 diabetes mellitus patients with kidney failure in 
comparison with type 2 diabetes mellitus patients with normo-, micro- or even 
macroalbumnuria (Hirata K. & Kubo K. 2004). While Wagner Z. et collegues 
demonstrated normal levels of CML and AGEs (fluorescence) in patients with type 2 
diabetes mellitus who had normal renal function (Wagner Z. et al., 2001). Since we 
excluded patients with CAD or kidney disturbances, those factors did not influences CML 
concentration, in plasma in our investigated groups. Thus, the determined CML 
concentration in plasma did not follow increased accumulation in the body. Baumann M. 
and colleagues found that CML might be accumulated in tissues, what could lead to 
different metabolic complications (Baumann M., 2009).    
Interesting work showed Dworacka M. et colleagues. Their results revealed significantly 
higher CML in non-diabetic patients with coronary heart disease than in healthy control 
subjects and were comparable to serum CML in patients with type 2 diabetes mellitus 
without late complications and coronary heart disease (Dworacka M. et al., 2002). In our 
study we realized higher (but not significant) CML concentration in subgroup defined as 
normoglycemic. This patients had lower total cholesterol, LDL-C and triglicerydes and 
higher HDL-C in comparison with prediabetics.  Thus it is possible that complications of 
diabetes mellitus are themselves related to pathobiochemical alterations other than protein 
glycation i.e. oxidative stress and lipids peroxidation.  
There is no doubt that elevated CML are closely associated with late complication of 
hyperglycemia in patients with type 2 diabetes mellitus or atherosclerotic angiopathies. 
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Further studies should be performed in patients with the very early stages of dysglycemia to 
find when the pathology starts.  
Different tendencies for HbA1c and fructosamine and CML were observed while IFG or IGT 
were separated (as in table 7). Based on HbA1c IGT group seems to be more advanced on the 
way to diabetes. However IFG individuals tended to present higher fructosamine and CML 
which may reflect not only glycation. There is no literature data concerning different 
metabolic aspect of IFG or IGT in elderly, but in middle aged population Faerch K. et al. 
showed different insulin action and incretin hormone concentration suggesting different 
management according to the prediabitic subgroup diagnosis (Faerch K. et al., 2008). 
Despite some answers our study has brought, that there are some challenges for the future 
investigations that should be coped. What biomarker could predict the increased risk related 
to dysglycemia in elderly patients? Does the kind of prediabetes state matter, in a context of 
metabolic complications, especially in elderly patients?   
5. Conclusions 
There is no doubt that elevated fructosamine, HbA1c and CML are closely associated with late 
complication of hyperglycemia in patients with type 2 diabetes mellitus or atherosclerotic 
angiopathy. The best marker in dysglycemic but not yet diabetic elderly patients seems to be 
only glycated hemoglobin. When Nε-carboxymethyllysine and fructosamine as a single 
marker seem to be not good enough prognostic indicators of dysglycemia. In apparently 
healthy elderly people otherwise with no diagnosed comorbidities but with hyperglycemia, 
clinical assessment and laboratory investigations of hyperglycemia complications may help 
in prevention all global complications. In our opinion CML and/or fructosamine may result 
from different metabolic pathways (i.e. glycation and oxidative stress). 
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